MS Australia CEO Rohan Greenland discusses the need for a national minimum neurological data set to ensure the 1.6m Australians living with these conditions can receive the resources and support required.
The European Committee for Treatment and Research in MS, seen as the pinnacle of scientific and medical research into multiple sclerosis, held its annual meeting in Amsterdam last month. This article provides an overview of some of the key highlights of the conference.
A large international study shows that people living with secondary progressive multiple sclerosis experience different progression trajectories.
Bronwyn spent her childhood watching her mother live with advancing MS. Then she was diagnosed with MS when she was just 25. Now, as a mother of two daughters, she looks to MS research to give her hope for a better tomorrow.
MSisters Kat and Sarah took on the challenge to fundraise for Kiss Goodbye to MS to ensure vital research continues into treatments and a cure for multiple sclerosis.
Living with multiple sclerosis often means high energy use, which results in significant expenses when combined with rising energy costs. However, there are energy concessions that you may be eligible for to help reduce your energy bill.
From 1 December 2022, REBIF will no longer be available on the PBS for Australians living with MS. For people with MS who are currently being treated with REBIF, it is important to note that while the therapy will be removed from the PBS from 1 December 2022, REBIF scripts will still be filled until 1 April 2023.Â
A ground-breaking clinical trial has found that vitamin D supplements do not prevent multiple sclerosis development in people at high risk. We look at the questions yet to be answered from this clinical trial and what the results mean for people with MS.
That’s the finding from PrevANZ, a ground-breaking clinical trial funded by MS Australia to determine if oral vitamin D supplements can delay the onset of MS.
